Neurocognitive effects of ketamine in treatment-resistant major depression: Association with antidepressant response

Psychopharmacology

Volumn 231, Issue 3, 2014, Pages 481-488

  Murrough, James W ^a   Wan, Le Ben ^a   Iacoviello, Brian ^a   Collins, Katherine A ^a   Solon, Carly ^a   Glicksberg, Benjamin ^a   Perez, Andrew M ^a   Mathew, Sanjay J ^b,c   Charney, Dennis S ^a   Iosifescu, Dan V ^a   Burdick, Katherine E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antidepressant; Cognitive functioning; Glutamate; Ketamine; Major depressive disorder; N methyl d aspartate; Neurocognition; Treatment resistant depression

Indexed keywords

KETAMINE;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; COGNITION; COMPREHENSIVE BATTERY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MATRICS CONSENSUS COGNITIVE BATTERY; MATRIX REASONING; MEMORY; MENTAL PERFORMANCE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RECALL; TREATMENT RESISTANT DEPRESSION; TREATMENT RESISTANT MAJOR DEPRESSION; TREATMENT RESPONSE; WECHLSER ADULT INTELLIGENCE SCALE VOCABULARY; WIDE RANGE ACHIEVEMENT TEST 3 READING;

EID: 84892805424     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3255-x     Document Type: Article

References (40)

1. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139-145. doi: 10.1016/j.biopsych.2009.08.038
2. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch Gen Psychiatry 57:270-276
3. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95. doi: 10.1038/nature10130
4. Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN (2000) A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 47:332-337
5. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11:125-136. doi: 10.1023/A:1024465317902
6. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68-72. doi: 10.1126/science.1222939
7. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S (2000) Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 60:13-23
8. First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured Clinical Interview for DSM-IV Axis Disorders (SCID). New York State Psychiatric Institute, Biometrics Research, New York
9. Gorlyn M, Keilp JG, Grunebaum MF, Taylor BP, Oquendo MA, Bruder GE, Stewart JW, Zalsman G, Mann JJ (2008) Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm 115:1213-1219. doi: 10.1007/s00702-008-0084-x
10. Green SM, Li J (2000) Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med 7:278-281
11. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA Jr (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37:1526-1533. doi: 10.1038/npp.2011.338
12. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
13. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr, Vegso S, Heninger GR, Charney DS (1999) Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145:193-204
14. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D'Souza DC (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62:985-994. doi: 10.1001/archpsyc.62.9. 985
15. Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C Jr (2012) Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72:e27-e28. doi: 10.1016/j.biopsych.2012.05.031
16. Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA Jr (2012) Family history of alcohol dependence and antidepressant response to an N-methyl-d-aspartate antagonist in bipolar depression. Bipolar Disord 14:880-887. doi: 10.1111/bdi.12003
17. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13:71-82. doi: 10.1017/S1461145709000169
18. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012) Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26:189-204. doi: 10.2165/11599770-000000000-00000
19. McLennan SN, Mathias JL (2010) The depression-executive dysfunction (DED) syndrome and response to antidepressants: a meta-analytic review. Int J Geriatr Psychiatr 25:933-944. doi: 10.1002/gps.2431
20. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927
21. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
22. Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 157:1301-1317. doi: 10.1111/j.1476-5381.2009.00304.x
23. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004) Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29:208-218. doi: 10.1038/sj.npp.1300342
24. Morgan CJ, Muetzelfeldt L, Curran HV (2009) Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104:77-87. doi: 10.1111/j.1360-0443. 2008.02394.x
25. Murrough JW (2012) Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther 91:303-309. doi: 10.1038/clpt.2011.244
26. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250-256. doi: 10.1016/j.biopsych.2012.06. 022
27. Overall JE, Gorham DR, Shawver JR (1961) Basic dimensions of change in the symptomatology of chronic schizophrenics. J Abnorm Soc Psychol 63:597-602
28. Parwani A, Weiler MA, Blaxton TA, Warfel D, Hardin M, Frey K, Lahti AC (2005) The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berl) 183:265-274. doi: 10.1007/s00213-005-0177-2
29. Perry EB Jr, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O'Donnell E, Krystal JH, D'Souza DC, Yale Ketamine Study Group (2007) Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 192:253-260. doi: 10.1007/s00213-007-0706-2
30. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr (2009) Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biol Psychiatry 65:181-184. doi: 10.1016/j.biopsych.2008.09.029
31. Reich DL, Silvay G (1989) Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 36:186-197. doi: 10.1007/BF03011442
32. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA (2005) Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 30:633-639. doi: 10.1038/sj.npp.1300642
33. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996) The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 26:477-486
34. Sackeim HA (2001) The definition and meaning of treatment-resistant depression. J Clin Psychiatr 62(Suppl 16):10-17
35. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25. doi: 10.1016/S0893-133X(97)00092-4
36. Swardfager W, Herrmann N, Marzolini S, Saleem M, Shammi P, Oh PI, Albert PR, Daigle M, Kiss A, Lanctot KL (2011) Brain derived neurotrophic factor, cardiopulmonary fitness and cognition in patients with coronary artery disease. Brain Behav Immun 25:1264-1271. doi: 10.1016/j.bbi.2011.04.017
37. Taylor BP, Bruder GE, Stewart JW, McGrath PJ, Halperin J, Ehrlichman H, Quitkin FM (2006) Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry 163:73-78. doi: 10.1176/appi.ajp.163. 1.73
38. 11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35-43
39. Wechsler D (1999) Wechsler Abbreviated Scale of Intelligence (WASI). Harcourt Assessment, San Antonio
40. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864. doi: 10.1001/archpsyc.63.8.856